Home › Merck Statement on FDA Advisory Committee Meeting for RAGWITEK (Short Ragweed Pollen Allergen Extract), an Investigational Sublingual Allergy Immunotherapy Tablet
 

Keywords :   


Merck Statement on FDA Advisory Committee Meeting for RAGWITEK (Short Ragweed Pollen Allergen Extract), an Investigational Sublingual Allergy Immunotherapy Tablet

2014-01-29 03:26:07| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said it was pleased with the positive discussion of RAGWITEK (Short Ragweed Pollen Allergen Extract) at the Allergenic Products Advisory Committee meeting of the U.S. Food and Drug Administration (FDA). Language: English read more

Tags: short statement meeting committee

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.09Eastern North Pacific Tropical Weather Outlook
28.09Atlantic Tropical Weather Outlook
28.09Post-Tropical Cyclone Helene Public Advisory Number 21
28.09Tropical Storm Joyce Public Advisory Number 5
28.09Summary for Tropical Storm Joyce (AT1/AL112024)
28.09Post-Tropical Cyclone Helene Public Advisory Number 21
28.09Tropical Storm Joyce Forecast Discussion Number 5
28.09Tropical Storm Joyce Wind Speed Probabilities Number 5
More »